Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial

or

Watchlist | Portfolio

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
options
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Avidity Biosciences Inc (RNA)

Avidity Biosciences Inc (RNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1 PR Newswire - Sat Oct 7, 2023

New AOC 1001 data demonstrate improvement in additional functional measures including hand grip, muscle strength and patient reported outcomes, augmenting...

Avidity Biosciences to Participate in Upcoming Investor Conferences PR Newswire - Mon Sep 25, 2023

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Thu Sep 21, 2023

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023 FinancialNewsMedia - Wed Sep 13, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when...

Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs PR Newswire - Thu Sep 7, 2023

Avidity supports World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD and Global Genes Week in...

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Mon Aug 21, 2023

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping PR Newswire - Tue Aug 15, 2023

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights PR Newswire - Tue Aug 8, 2023

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Fri Jul 21, 2023

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Wed Jun 21, 2023

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Want to use this as
your default charts setting?

Save this setup as a Chart Templates

Switch the Market flag

for targeted data from your country of choice.

Open the menu and switch the
Market flag for targeted data from your country of choice.

Want Streaming Chart Updates?

Switch your Site Preferences
to use Interactive Charts

Need More Chart Options?

Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar